ZYDUS LIFESCIENCES LTD filed Apr–Jun 2026 on Tue 11 Aug 2026, read on its consolidated figures (the group).

Revenue was ₹8,017 crore, 22% above a year earlier; profit was ₹940 crore, 36% below a year earlier.

Over four quarters it kept 16 of every 100 rupees of revenue as profit.

Its borrowings were 40 in every 100 of its equity at 31 Mar 2026.

7 of the 9 conditions that could be measured held.

• Held: revenue over the last four quarters was above the four before.
• Held: profit over the last four quarters was above the four before.
• Held: profit over the last four quarters was above zero.
• Did not hold: the operating margin over the last four quarters held against the four before.
• Did not hold: cash from operations was at least 80 in every 100 of profit, latest full year.
• Held: borrowings were no more than equity.
• Held: profit before interest covered interest at least three times.
• Held: promoters had pledged at most 5 in every 100 of their shares.
• Held: promoters' holding did not fall more than one point in a year.

Healthcare, 20 other companies read for this quarter; revenue over four quarters 21% above the four before, against 14% above the four before for the typical company in the group; it kept 16 of every 100 rupees of revenue as profit, the typical company 12.

The group is its industry as NSE lists it today; each company is read on the quarter it had filed by then, and the company is left out of its own group.

At 30 Sep 2026: promoters held 75 in every 100 shares, foreign investors 7 in every 100, Indian institutions 11 in every 100 (mutual funds 7 in every 100).

Promoters had pledged 0 in every 100 of their shares.